Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

Share Price is delayed by 15 minutes
Get Live Data
28.50    0.25 (0.88%)
Bid:
28.00
Ask:
29.00
Spread: 1.00 (3.571%)
Market Cap: £56.68m
IKA Live PriceLast checked at - London Stock Exchange

Intraday Ilika Plc Share Chart

Half Year Trading Update

12 Nov 2013 07:00

RNS Number : 7510S
Ilika plc
12 November 2013
Β 

ο»Ώ

Ilika plc

("Ilika" or the "Company")

Β 

Half Year Trading Update

Β 

Ilika (AIM: IKA), the advanced materials discovery company, announces a trading update for the six months ended 31 October 2013. Ilika will announce Interim Results for the six months ended 31 October on 29 January 2014.

Β 

Operational Review

Β 

The Company has continued to make progress with developing and licensing its proprietary materials IP. With the goal of driving towards generating licensing revenue, Ilika is currently managing active OEM trials with two separate products from its portfolio: a polymer surface used for cell growth and a low-cost fuel cell catalyst. Technical development of these two products is substantially complete, with the focus now being on market introduction. The polymer is a heritage product from its biomaterial portfolio and is being out-licensed on Ilika's behalf by BioBM, a specialist life science marketing company. Following the delivery of a kg-scale quantity of its low cost fuel cell catalyst, OEM trials have commenced with three global OEM's and a trial with a further automotive OEM will commence in Q1 2014.Β 

Β 

Technology development activities are focused on the Company's solid-sate battery technology. Initial cell performance data have been encouraging and the focus of the programme is now shifting to stacking multiple cells to make higher capacity devices. The benefits of the technology remain of interest to a broad range of sectors spanning different battery scales including micro-batteries for wireless sensors, portable consumer electronics and larger scale automotive.

Β 

A new high growth sector for the Company's technology platform is the aerospace sector, where Ilika has entered into initial relationships with two of the world's largest aerospace companies. Further activities are expected to be supported by the Aerospace Technology Institute, which has recently been established to deploy Β£2 billion of funding for the UK aerospace industry over the next seven years.

Β 

Financial Review

Β 

Total revenue for the period has shown year-on-year growth of 55%, reaching Β£0.62m (H1 2012: Β£0.4m).

Β 

Ilika has expanded its active customer base in the period from five in the comparable period last year, to nine in the current year. The geographical spread of revenues has also become more balanced due to a stronger business development performance in Europe. In the previous year, 70% of revenues originated with Japanese customers, whereas in the current year to date, 45% of revenues have come from Europe and 45% from Japan. Business development efforts in the USA are expected result in an increased proportion of revenue in the second half.

Β 

Cash and cash equivalents at the period end were in excess of Β£1.4m

Β 

As announced previously, an overview of the business will be provided later today, Tuesday 12 November 2013, at the Black Bar at Rocket, 6 Adams Court, Old Broad Street, London, EC2N 1DX and will be followed by drinks and canapΓ©s. If you wish to attend please contact Walbrook PR Ltd.

Β 

Β 

Ilika plc

www.ilika.com

Graeme Purdy, Chief Executive

Tel: 023 8011 1400

Steve Boydell, Finance Director

Β 

Β 

Β 

Numis Securities Limited

Tel: 020 7260 1000

Oliver Cardigan, Nominated Adviser

Β 

James Black, Corporate Broking

Β 

Β 

Β 

Walbrook PR Ltd

Tel: 020 7933 8780 or ilika@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Paul Cornelius

Mob: 07827 879 460

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTFFLFUFFDSESF
Date   Source Headline
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
16th Dec 20224:40 pmRNSSecond Price Monitoring Extn
16th Dec 20224:35 pmRNSPrice Monitoring Extension
21st Nov 20221:29 pmEQSIlika 'well positioned' to deliver battery product combination
17th Nov 20224:40 pmRNSSecond Price Monitoring Extn
17th Nov 20224:35 pmRNSPrice Monitoring Extension
17th Nov 20229:05 amRNSSecond Price Monitoring Extn
17th Nov 20229:00 amRNSPrice Monitoring Extension
17th Nov 20227:01 amRNSAppointment of Chief Financial Officer
17th Nov 20227:00 amRNSTrading Update, Notice of Results & Presentations
22nd Sep 202212:45 pmRNSExercise of Options, PDMR Shareholding and TVR
20th Sep 20224:47 pmRNSResult of AGM
7th Sep 202210:00 amRNSGoliath Scale-up Update
18th Aug 20227:00 amRNSPosting of Annual Report and Notice of AGM
1st Aug 20229:05 amRNSSecond Price Monitoring Extn
1st Aug 20229:00 amRNSPrice Monitoring Extension
25th Jul 20223:30 pmRNSHolding(s) in Company
20th Jul 20222:05 pmRNSSecond Price Monitoring Extn
20th Jul 20222:00 pmRNSPrice Monitoring Extension
14th Jul 20227:00 amRNSExercise of Options and Total Voting Rights
13th Jul 20224:41 pmRNSSecond Price Monitoring Extn
13th Jul 20224:36 pmRNSPrice Monitoring Extension
13th Jul 20227:00 amRNSFinal Results
20th Jun 20227:00 amRNSGoliath Scale-up Update
11th May 20227:00 amRNSTrading Update & Notice of Results
4th May 20227:00 amRNSGoliath Scale-up Update
21st Mar 202211:45 amRNSDirector/PDMR Shareholding
15th Mar 202212:34 pmRNSDirector/PDMR Shareholding
25th Feb 20227:00 amRNSDirectorate Change
24th Feb 20222:01 pmRNSPrice Monitoring Extension
8th Feb 20227:00 amRNSAward of Share Options
7th Feb 202211:01 amRNSPrice Monitoring Extension
20th Jan 20227:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSFirst Stereax Manufacturing Facility Opened
23rd Nov 20215:11 pmRNSHolding(s) in Company
19th Nov 20217:00 amRNSTrading Update & Notice of Half-year Results
10th Nov 20217:00 amRNSCapital Markets Day
22nd Sep 20213:30 pmRNSResult of AGM and Award of Bonus Share Options
10th Sep 20217:00 amRNSCommencement of trading on OTCQX Best Market in US
7th Sep 20217:00 amRNSSenior Appointments and Change of Director
24th Aug 20217:00 amRNSStereax Manufacturing Update
20th Aug 20217:00 amRNSNotice of AGM & Posting of Annual Report
5th Aug 20219:16 amRNSExercise of Options and Total Voting Rights
30th Jul 20214:32 pmRNSHolding(s) in Company
30th Jul 20219:54 amRNSDirector/PDMR Shareholding
29th Jul 20219:00 amRNSExercise of Options and Total Voting Rights
28th Jul 20211:14 pmRNSResults of GM, Open Offer and Total Voting Rights
12th Jul 202112:30 pmRNSPosting of Circular
9th Jul 20214:07 pmRNSResult of Placing and Retail Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.